as 05-20-2024 4:00pm EST
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | BELGRADE |
Market Cap: | 106.7M | IPO Year: | N/A |
Target Price: | $2.10 | AVG Volume (30 days): | 167.7K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.01 | EPS Growth: | N/A |
52 Week Low/High: | $0.60 - $1.45 | Next Earning Date: | 05-15-2024 |
Revenue: | $101,232,000 | Revenue Growth: | 60.81% |
Revenue Growth (this year): | 28.47% | Revenue Growth (next year): | 13.35% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Brandt Kevin D | XTNT | Chief Commercial Officer | Nov 17 '23 | Buy | $1.20 | 41,670 | $49,837.32 | 815,860 | SEC Form 4 |
XTNT Breaking Stock News: Dive into XTNT Ticker-Specific Updates for Smart Investing
GuruFocus.com
5 days ago
ACCESSWIRE
5 days ago
ACCESSWIRE
12 days ago
GlobeNewswire
21 days ago
Insider Monkey
2 months ago
Thomson Reuters StreetEvents
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago